Topical cocaine can treat ABMD

Article

Cocaine-assisted epithelial debridement is a simple and inexpensive treatment method for symptomatic anterior basement membrane dystrophy (ABMD) patients, reveals the latest study in the journal Cornea.

Cocaine-assisted epithelial debridement is a simple and inexpensive treatment method for symptomatic anterior basement membrane dystrophy (ABMD) patients, reveals the latest study in the journal Cornea.

Dr Rony R. Sayegh et al., Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA, conducted a retrospective chart review on 33 eyes of 27 symptomatic patients with ABMD who were treated with 4% topical cocaine followed by epithelial debridement.

The main outcome measures included preoperative and postoperative best-corrected visual acuities (BCVA), topography, subjective symptoms, complications and evidence of disease recurrence.

Recurrent erosion symptoms were present in 17 eyes of 14 patients (group 1) and 16 eyes of 13 patients (group 2) experienced reduced visual acuity from irregular astigmatism.

Group 1 presented with one patient who experienced symptomatic recurrence of the corneal erosion. In group 2 one patient experienced significant postoperative corneal haze. BCVA in group 1 improved from an average of 20/45 preoperatively to 20/38 at the last follow-up visit and 20/63 to 20/32 in group 2.

The treatment is ideal for ABMD patients who experience recurrent corneal erosions or irregular astigmatism, causing decreased visual acuity.

Please click here to read the study abstract.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.